CR20220067A - Agentes antipalúdicos - Google Patents

Agentes antipalúdicos

Info

Publication number
CR20220067A
CR20220067A CR20220067A CR20220067A CR20220067A CR 20220067 A CR20220067 A CR 20220067A CR 20220067 A CR20220067 A CR 20220067A CR 20220067 A CR20220067 A CR 20220067A CR 20220067 A CR20220067 A CR 20220067A
Authority
CR
Costa Rica
Prior art keywords
plasmepsin
compounds
administration
treating
formula
Prior art date
Application number
CR20220067A
Other languages
English (en)
Inventor
Iii Michael J Kelly
Lera Ruiz Manuel De
Brad Sleebs
Jennifer K Thompson
John A Mccauley
Lianyun Zhao
Cailing Zhang
Alan F Cowman
Dongmei Zhan
Paola Favuzza
Zhiyu Lei
David B Olsen
Tony Triglia
Zhuyan Guo
Bin Hu
Original Assignee
Merck Sharp & Dohme
Walter & Eliza Hall Inst Medical Res
Msd R&D China Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Walter & Eliza Hall Inst Medical Res, Msd R&D China Co Ltd filed Critical Merck Sharp & Dohme
Publication of CR20220067A publication Critical patent/CR20220067A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona métodos para el tratamiento contra la malaria que comprende la administración de compuestos de la Fórmula (I'): o una sal de este farmacéuticamente aceptable, a un sujeto que lo necesite, en donde las variables son como se definen en la presente. La invención también proporciona usos de los compuestos de la Fórmula (I), como se define en la presente, para inhibir la actividad de plasmepsina X, plasmepsina IX o plasmepsina X y IX, para el tratamiento contra la infección de Plasmodium, y para el tratamiento contra la malaria. También se proporciona métodos de tratamiento que comprenden además la administración de uno o más compuestos antipalúdicos.
CR20220067A 2019-08-15 2020-07-21 Agentes antipalúdicos CR20220067A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/100781 WO2021026884A1 (en) 2019-08-15 2019-08-15 Antimalarial agents
PCT/CN2020/103178 WO2021027502A1 (en) 2019-08-15 2020-07-21 Antimalarial agents

Publications (1)

Publication Number Publication Date
CR20220067A true CR20220067A (es) 2022-04-20

Family

ID=74570489

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220067A CR20220067A (es) 2019-08-15 2020-07-21 Agentes antipalúdicos

Country Status (20)

Country Link
US (1) US20220331321A1 (es)
EP (1) EP4013742A4 (es)
JP (1) JP7116859B2 (es)
KR (1) KR20220047312A (es)
CN (1) CN114555564B (es)
AR (1) AR119784A1 (es)
AU (1) AU2020328678B2 (es)
BR (1) BR112022002692A2 (es)
CA (1) CA3147665C (es)
CL (1) CL2022000329A1 (es)
CO (1) CO2022001342A2 (es)
CR (1) CR20220067A (es)
DO (1) DOP2022000037A (es)
EC (1) ECSP22011746A (es)
IL (1) IL290525A (es)
JO (1) JOP20220038A1 (es)
MX (1) MX2022001768A (es)
TW (1) TW202115041A (es)
UA (1) UA128074C2 (es)
WO (2) WO2021026884A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023102747A1 (en) * 2021-12-07 2023-06-15 Merck Sharp & Dohme Llc Antimalarial agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
UA108363C2 (uk) * 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US11136310B2 (en) * 2015-11-25 2021-10-05 UCB Biopharma SRL Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors
EP3416647A4 (en) * 2016-02-18 2019-10-23 Merck Sharp & Dohme Corp. N3-SUBSTITUTED IMINOPYRIMIDINONES AS ANTIMALARIAL AGENTS
GB201603104D0 (en) * 2016-02-23 2016-04-06 Ucb Biopharma Sprl Therapeutic agents
GB201906804D0 (en) 2019-05-14 2019-06-26 Ucb Biopharma Sprl Therapeutic agents
WO2021155612A1 (en) * 2020-02-09 2021-08-12 Merck Sharp & Dohme Corp. Antimalarial agents

Also Published As

Publication number Publication date
US20220331321A1 (en) 2022-10-20
EP4013742A4 (en) 2023-07-12
MX2022001768A (es) 2022-06-09
BR112022002692A2 (pt) 2022-09-27
AU2020328678B2 (en) 2023-02-02
CN114555564A (zh) 2022-05-27
CN114555564B (zh) 2024-01-30
TW202115041A (zh) 2021-04-16
JOP20220038A1 (ar) 2023-01-30
KR20220047312A (ko) 2022-04-15
JP7116859B2 (ja) 2022-08-10
AU2020328678A1 (en) 2022-03-03
EP4013742A1 (en) 2022-06-22
WO2021027502A1 (en) 2021-02-18
DOP2022000037A (es) 2022-06-30
WO2021026884A1 (en) 2021-02-18
CL2022000329A1 (es) 2022-10-07
JP2022534454A (ja) 2022-07-29
AR119784A1 (es) 2022-01-12
CO2022001342A2 (es) 2022-05-20
CA3147665A1 (en) 2021-02-18
IL290525A (en) 2022-04-01
UA128074C2 (uk) 2024-03-27
ECSP22011746A (es) 2023-01-31
CA3147665C (en) 2023-11-28

Similar Documents

Publication Publication Date Title
WO2017142825A3 (en) N3-substituted iminopyrimidinones as antimalarial agents
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
TW200518758A (en) HIV replication inhibiting purine derivatives
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
PH12015501445B1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
NZ588217A (en) Spiro-indole derivatives for treating malaria, leishmaniasis and Chagas disease
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2023009521A (es) Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d.
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MX2019010695A (es) Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2 h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones.
MX2022012056A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
IN2012DN01684A (es)
CR20210364A (es) Compuestos de quinolina como inhibidores de quinasas tam y met
CR20220067A (es) Agentes antipalúdicos
MX2023007579A (es) Derivado de borato y usos del mismo.
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2010002679A (es) Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
MX2023011297A (es) Antagonista del dominio de alfa/beta hidrolasa 6 (abhd6).
FI3448430T3 (fi) Asetyylikoleeniesteraasi-inhibiittorin ja idalopirdiinin käyttö Parkinsonin taudin potilaiden kaatumisten vähentämiseksi